-Alicja Bielawska Researcher Activity Profile

Research Author Detailed Information 

Alicja Bielawska Publication Rate By Year

Alicja Bielawska has published 1 paper(s) in 2003, 4 paper(s) in 2006, 12 paper(s) in 2007, 8 paper(s) in 2008, for a total of 25 research publications in total.

Alicja A Bielawska Author Information

LAST NAME: bielawska

FIRST NAME: alicja

INITIALS: A

AFFILIATION:

Papers

Alicja Bielawska's Publication Record

1. Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Year Published: 2006
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, 29425, USA.
2. Involvement of sphingolipids in apoptin-induced cell killing. Year Published: 2006
Department of Microbiology and Immunology, Medical University of South Carolina, P.O. Box 250504, 173 Ashley Avenue, Charleston, SC 29425, USA.
3. Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens. Year Published: 2007
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA.
4. Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. Year Published: 2007
Division of Hematology/Oncology, Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425, USA. kravekjm@musc.edu
5. Role of Acid Ceramidase in Resistance to FasL: Therapeutic Approaches Based on Acid Ceramidase Inhibitors and FasL Gene Therapy. Year Published: 2007
1Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.
6. JNK3 signaling pathway activates ceramide synthase leading to mitochondrial dysfunction. Year Published: 2007
Ralph H. Johnson Veterans Affairs Medical Center, and the Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
7. Maternal disturbance in activated sphingolipid metabolism causes pregnancy loss in mice. Year Published: 2007
Genetics of Development and Disease Branch, NIDDK, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA.
8. Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens. Year Published: 2007
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA.
9. Acid ceramidase inhibition: a novel target for cancer therapy. Year Published: 2007
Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.
10. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Year Published: 2007
Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29403, USA, norrisjs@musc.edu.
11. Acid ceramidase inhibition: a novel target for cancer therapy. Year Published: 2007
Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.
12. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Year Published: 2007
Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29403, USA.
13. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Year Published: 2008
Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
14. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Year Published: 2008
Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
15. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Year Published: 2007
Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29403, USA.
16. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Year Published: 2008
John Wayne Cancer Institute at Saint John's Health Center, Department of Experimental Therapeutics, Santa Monica, CA 90404, USA.
17. Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents. Year Published: 2008
Department of Biochemistry & Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, POB 250509, Charleston, SC 29425, USA.
18. Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Year Published: 2008
Department of Biochemistry & Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, PO Box 250509, Charleston, SC 29425, USA. bielawsk@musc.edu
19. Cloning and characterization of a mouse endoplasmic reticulum alkaline ceramidase: an enzyme that preferentially regulates metabolism of very long chain ceramides. Year Published: 2003
Department of Medicine, Medical University of South Carolina, Charleston 29425, USA. maoc@musc.edu
20. Neutral ceramidase encoded by the Asah2 gene is essential for the intestinal degradation of sphingolipids. Year Published: 2006
Genetics of Development and Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
21. Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents. Year Published: 2008
Department of Biochemistry & Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, POB 250509, Charleston, SC 29425, USA.
22. Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Year Published: 2008
Department of Biochemistry & Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, PO Box 250509, Charleston, SC 29425, USA. bielawsk@musc.edu
23. Involvement of sphingolipids in apoptin-induced cell killing. Year Published: 2006
Department of Microbiology and Immunology, Medical University of South Carolina, P.O. Box 250504, 173 Ashley Avenue, Charleston, SC 29425, USA.
24. Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Year Published: 2007
Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.
25. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Year Published: 2008
John Wayne Cancer Institute at Saint John's Health Center, Department of Experimental Therapeutics, Santa Monica, CA 90404, USA.